Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$37.68 USD

37.68
3,255,904

+0.12 (0.32%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $37.68 0.00 (0.00%) 7:56 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

The Zacks Analyst Blog Highlights: Chevron, Glaxo, T-Mobile, Delta Air Lines and American Water Works

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Chevron, Glaxo, T-Mobile, Delta Air Lines and American Water Works

    Zacks Equity Research

    Merck's (MRK) Keytruda Gets FDA Approval for Cervical Cancer

    by Zacks Equity Research

    Merck's (MRK) Keytruda receives accelerated approval for the treatment of patients with advanced cervical cancer.

      Mark Vickery headshot

      Top Stock Reports for Chevron, Glaxo & T-Mobile

      by Mark Vickery

      Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), Glaxo (GSK) and T-Mobile (TMUS).

        Zacks Equity Research

        Pfizer Boosts Venture Capital Efforts, Neuroscience in Focus

        by Zacks Equity Research

        Pfizer (PFE) to pour $600 million in its venture capital arm. About 150 million will be earmarked for companies involved in promising early-stage neuroscience research.

          Zacks Equity Research

          Merck Presents Positive Melanoma Data on Keytruda at ASCO

          by Zacks Equity Research

          Merck (MRK) presents encouraging data from two pivotal advanced melanoma studies on its PD-L1 inhibitor, Keytruda.

            Zacks Equity Research

            LabCorp, Unilabs Tie Up to Expand in Companion Diagnostics

            by Zacks Equity Research

            LabCorp (LH) continues to strengthen hold in the diagnostics space through inorganic means.

              Zacks Equity Research

              Novartis Announces Positive Data on Kisqali and Tasigna

              by Zacks Equity Research

              Novartis (NVS) announces positive data on breast cancer drug Kisqali and oncology drug Tasigna at the ASCO.

                Zacks Equity Research

                Merck's (MRK) Keytruda Lung Cancer Data in Focus at ASCO

                by Zacks Equity Research

                Merck (MRK) presents data from several cancer studies of its PD-L1 inhibitor, Keytruda at ASCO including two key lung cancer trials.

                  Zacks Equity Research

                  LabCorp Extends Aetna Agreement, Expands Diagnostics Business

                  by Zacks Equity Research

                  The expanded agreement enables LabCorp (LH) to serve as a preferred national laboratory to almost all of Aetna's members starting Jan 1, 2019.

                    Zacks Equity Research

                    Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan

                    by Zacks Equity Research

                    Glaxo and Innoviva file for approval of Trelegy Ellipta in Japan for the treatment of COPD.

                      Zacks Equity Research

                      AstraZeneca (AZN) Stock on Growth Path This Year: Here's Why

                      by Zacks Equity Research

                      AstraZeneca's (AZN) stock is up this year while the Large-Cap Pharma industry is witnessing a decline

                        Zacks Equity Research

                        The Zacks Analyst Blog Highlights: Cisco, Kraft Heinz, Sinopec, Glaxo and Progressive

                        by Zacks Equity Research

                        The Zacks Analyst Blog Highlights: Cisco, Kraft Heinz, Sinopec, Glaxo and Progressive

                          Zacks Equity Research

                          Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval

                          by Zacks Equity Research

                          Glaxo (GSK) and partner J&J (JNJ) gain marketing approval in the EU for Juluca, a two-drug HIV treatment.

                            Zacks Equity Research

                            AstraZeneca's (AZN) Asthma Drug Fasenra Fails in COPD Study

                            by Zacks Equity Research

                            AstraZeneca's (AZN) asthma drug Fasenra (benralizumab) fails to meet the primary endpoint in a late-stage study evaluating it for a new indication - COPD.

                              Zacks Equity Research

                              Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View

                              by Zacks Equity Research

                              Emergent's (EBS) earnings and revenues lag estimates in Q1. However, the top line improves marginally year over year, driven by higher contract manufacturing revenues.

                                Zacks Equity Research

                                Merck (MRK) Beats on Q1 Earnings, Lags Sales, Raises Outlook

                                by Zacks Equity Research

                                Merck (MRK) beats estimates for earnings but misses the same for sales in Q1. Sales of Keytruda remain strong in the quarter.

                                  Zacks Equity Research

                                  HIV Segment to Aid Gilead (GILD) Beat Q1 Earnings Estimates?

                                  by Zacks Equity Research

                                  Gilead (GILD) is likely to report an earnings beat in the first-quarter (results due on May 1) driven by its HIV franchise strength.

                                    Zacks Equity Research

                                    Glaxo (GSK) Q1 Earnings Lag, Shingrix Vaccines Sales Solid

                                    by Zacks Equity Research

                                    Glaxo's (GSK) Q1 earnings fall short of estimates while revenues rise year over year. The company's vaccine segment performs strongly on the back of Shingrix sales.

                                      Zacks Equity Research

                                      What's in the Cards for Merck (MRK) This Earnings Season?

                                      by Zacks Equity Research

                                      Merck's (MRK) new products like Keytruda and Bridion are likely to drive first-quarter sales. However, headwinds remain in the form genericization of key drugs and increasing competition.

                                        Zacks Equity Research

                                        Glaxo (GSK) Misses on both Earnings and Revenue in Q1

                                        by Zacks Equity Research

                                        Glaxo's (GSK) Q1 earnings and revenue miss estimates. In the event of introduction of Advair generic in the U.S. market by mid-year, Glaxo expects adjusted EPS to be flat to down at CER in 2018.

                                          Zacks Equity Research

                                          What's in the Cards for Glaxo (GSK) This Earnings Season?

                                          by Zacks Equity Research

                                          Strong sales in Glaxo's (GSK) Pharmaceuticals and Vaccines business segment might aid the company's results in Q1.

                                            Zacks Equity Research

                                            Novartis (NVS) Beats Earnings and Revenue Estimates in Q1

                                            by Zacks Equity Research

                                            Novartis reported encouraging results for the first quarter as sales and earnings both topped expectations on Cosentyx and Entresto strength.

                                              Zacks Equity Research

                                              Sanofi to Divest European Generic Unit, Streamline Business

                                              by Zacks Equity Research

                                              Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.

                                                Zacks Equity Research

                                                Rigel Pharmaceuticals' (RIGL) Stock Gains 16%: Here's Why

                                                by Zacks Equity Research

                                                Shares of Rigel (RIGL) rise given that the FDA's decision on its lead pipeline candidate Tavalisse is nearing.

                                                  Zacks Equity Research

                                                  Is J&J's (JNJ) Pharma Segment Likely to Drive Q1 Earnings?

                                                  by Zacks Equity Research

                                                  The positive trend seen in J&J's (JNJ) pharma segment sales in the second half of 2017 is likely to continue in Q1.